Procept BioroboticsPRCT
PRCT
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
106% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 31
53% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 75
29% more call options, than puts
Call options by funds: $19.5M | Put options by funds: $15.1M
11% more funds holding
Funds holding: 247 [Q3] → 275 (+28) [Q4]
9% more capital invested
Capital invested by funds: $3.72B [Q3] → $4.05B (+$337M) [Q4]
3.36% more ownership
Funds ownership: 89.65% [Q3] → 93.01% (+3.36%) [Q4]
13% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 7 (-1) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$90
58%
upside
Avg. target
$93
62%
upside
High target
$95
66%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Morgan Stanley Patrick Wood 50% 1-year accuracy 6 / 12 met price target | 66%upside $95 | Overweight Maintained | 26 Feb 2025 |
Truist Securities Richard Newitter 51% 1-year accuracy 22 / 43 met price target | 58%upside $90 | Buy Reiterated | 26 Feb 2025 |
Financial journalist opinion
Based on 3 articles about PRCT published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomized, multicenter trial Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomized, multicenter trial
Neutral
GlobeNewsWire
2 weeks ago
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada
SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Venetian Hotel in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time.
Positive
Seeking Alpha
3 weeks ago
Procept BioRobotics: Strong Growth, But Profitability Seems Far Away
PROCEPT BioRobotics shows strong revenue growth and expanding market presence but struggles with profitability and rising operational costs. The company's HYDROS robotic system and consumables business are driving revenue, with significant expansion in the U.S. and promising international growth. The FDA's clearance for Aquablation therapy in prostate cancer patients presents a long-term opportunity, though profitability remains a distant goal.
Neutral
Zacks Investment Research
1 month ago
PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Tops Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.54 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results
SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and year ended December 31, 2024.
Neutral
GlobeNewsWire
1 month ago
PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference
SAN JOSE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2024 after market close on Tuesday, February 25, 2025. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Positive
Zacks Investment Research
2 months ago
PROCEPT BioRobotics (PRCT) Upgraded to Strong Buy: Here's What You Should Know
PROCEPT BioRobotics (PRCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Business Wire
2 months ago
Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on PROCEPT BioRobotics (NASDAQ: PRCT)
NEW YORK--(BUSINESS WIRE)--Spruce Point Capital Management, LLC (“Spruce Point” or “we” or “us”), a New York-based investment management firm that focuses on forensic research and short-selling, today issued a detailed report entitled, “Pulling Back the Curtain on Procept,” that outlines why we believe and estimate that shares of PROCEPT BioRobotics (Nasdaq: PRCT) (“Procept” or the “Company”) face up to 30% – 60% potential long-term downside to approximately $29 - $54 per share and has market u.
Neutral
GlobeNewsWire
4 months ago
PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 36th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, December 4 at 8:30 a.m. Eastern Time.
Positive
Seeking Alpha
4 months ago
Procept BioRobotics: Continued Growth Runway Ahead
PRCT's Q3 sales were up 66% YoY, and gross margins reached a record 63%. Management forecasts $223mm in sales this year, with a 64% top-line growth. The business model ensures recurring revenue and operating leverage.
Charts implemented using Lightweight Charts™